---

Management of Platinum-Resistant Ovarian Cancer: A Detailed Overview

---

1. Definition and Classification

The distinction matters: patients with PFI <6 months should NOT receive further platinum, as response rates are low (<10% for refractory) and toxicity outweighs benefit. - Berek & Novak's Gynecology, p. 2367

---

2. General Principles of Treatment

• Single-agent non-platinum chemotherapy is the standard backbone (combination regimens increase toxicity without survival benefit)
• Biomarker testing is now mandatory before treatment selection: folate receptor alpha (FRα) expression, BRCA1/2 mutation status
• Bevacizumab improves PFS and ORR when added to chemotherapy (AURELIA trial), but no OS benefit
• Mirvetuximab soravtansine (MIRV) is the first agent to demonstrate an OS benefit in platinum-resistant disease (MIRASOL trial)
• Clinical trials should always be considered as a first option
• Goals are typically palliative: symptom control, quality of life, disease stabilization

---

3. Biomarker Testing - The Gateway to Treatment Selection

ALL platinum-resistant patients:
         |
         ├── FRα expression testing (IHC)
         |       ├── High (≥75% cells with ≥2+ staining) → MIRV eligible
         |       └── Low/negative → Conventional chemotherapy ± bevacizumab
         |
         ├── BRCA1/2 mutation (germline + somatic)
         |       ├── BRCA-mutated → Rucaparib (PARP inhibitor) option
         |       └── BRCA wild-type → Standard chemotherapy
         |
         ├── MSI/MMR status (dMMR/MSI-H tumors - rare in ovarian)
         |       └── Pembrolizumab consideration
         |
         └── Prior therapy history (platinum, taxane, bevacizumab, PARPi)

---

4. Approved Chemotherapy Options

4A. Single-Agent Chemotherapy

• Berek & Novak's Gynecology, p. 2368-2369: "There does not appear to be one best treatment. Single-agent therapy is typically used because combination regimens are associated with more toxicity without any apparent additional benefit."

Comparative Trial Data Summary

---

5. Targeted Therapy: Bevacizumab

AURELIA Trial (Key Phase III Data)

• 361 patients with platinum-resistant, bevacizumab-naive ovarian cancer
• Randomized to chemotherapy (paclitaxel/topotecan/PLD) +/- bevacizumab 15 mg/kg q3w
• Result: Chemotherapy + bevacizumab significantly improved PFS (HR 0.48; p<0.001) and ORR vs chemotherapy alone
• Best combination: Paclitaxel + bevacizumab: PFS 10 months vs 4 months (HR 0.46)
• No OS benefit demonstrated
• Key restriction: Only in bevacizumab-naive patients; maximum 2 prior lines

---

6. Mirvetuximab Soravtansine (MIRV) - The Breakthrough Agent

Mechanism

MIRASOL Trial (NEJM 2023, PMID 38055253) - Phase III Landmark

This is the first platinum-resistant ovarian cancer trial to demonstrate a statistically significant OS benefit - a historic result. (Systematic review PMID 39878268: "Only MIRASOL had statistically significant overall survival improvement" among 15 phase III trials in PROC).

Meta-analysis Data (PMID 38122916)

• Pooled ORR: 36% (95%CI 27-45%)
• Disease control rate: 88%
• Median PFS in platinum-resistant subset: 6.26 months

Patient-Reported Outcomes (Lancet Oncol 2025, PMID 40179908)

• MIRV significantly improved patient-reported outcomes vs chemotherapy
• Better quality of life scores compared to standard chemotherapy

FDA/EMA Status

• FDA full approval: March 2024 (based on MIRASOL)
• European Commission approval: November 2024
• Indication: Adult patients with FR-α-high (≥75% cells, ≥2+ staining), platinum-resistant high-grade serous EOC, 1-3 prior lines
• Boxed warning: Ocular toxicity (blurred vision - most common grade 1/2; mandatory ophthalmology monitoring)

ESMO 2026 Express Update Recommendation

MIRV Key Adverse Events

---

7. PARP Inhibitors in Platinum-Resistant Disease

Important 2022-2024 Update: Following FDA voluntary withdrawal announcements and safety signal reviews (myelodysplasia/AML risk with long-term use, potential OS detriment in unselected populations), NCCN downgraded all PARP inhibitors from Category 2A (Preferred) to Category 3 (Other Recommended) in platinum-resistant settings. [NCCN v3.2024]

• Patient has BRCA1/2 mutation
• No prior PARP inhibitor exposure
• Used in ≥3rd line

---

8. Treatment Selection Flowchart

PLATINUM-RESISTANT OVARIAN CANCER
(PFI <6 months / platinum-refractory)
              |
              v
   ┌─────────────────────────────────────┐
   │  Step 1: BIOMARKER EVALUATION       │
   │  - FRα IHC (mandatory)              │
   │  - BRCA1/2 status                   │
   │  - Prior bevacizumab exposure       │
   │  - Prior PARPi exposure             │
   │  - Number of prior lines            │
   │  - PS / comorbidities               │
   └─────────────────────────────────────┘
              |
    ┌─────────┴──────────┐
    |                    |
FRα HIGH               FRα LOW / NEGATIVE
(≥75% cells, ≥2+)      (or unknown)
    |                    |
    v                    v
MIRVETUXIMAB       ┌─────────────────────────┐
SORAVTANSINE       │  BRCA-mutated?           │
(1st choice in     │  + PARPi naive?          │
 FRα-high,         │  + ≥3 prior lines?       │
 1-3 prior lines)  └────────┬────────────────┘
                             |
                   ┌─────────┴──────────┐
                   YES                  NO
                   |                    |
                   v                    v
            PARP INHIBITOR      NON-PLATINUM CHEMO
            (olaparib/rucaparib  ± BEVACIZUMAB
            - Cat 3, NCCN)
                             |
                    ┌────────┴────────────┐
                    |                     |
              BEVACIZUMAB           BEVACIZUMAB
               NAIVE                 PRIOR USE
                    |                     |
                    v                     v
            CHEMO + BEVACIZUMAB     SINGLE-AGENT
            (preferred combo)        CHEMO ONLY

---

9. Factors Determining Choice of Chemotherapy

┌──────────────────────────────────────────────────────────────────┐
│           FACTORS DECIDING CHEMOTHERAPY CHOICE                   │
│                 IN PLATINUM-RESISTANT OC                         │
├─────────────────────┬────────────────────────────────────────────┤
│ FACTOR              │ INFLUENCE ON CHOICE                        │
├─────────────────────┼────────────────────────────────────────────┤
│ FRα Expression      │ High → MIRV (first choice per ESMO/NCCN)   │
│                     │ Low/neg → Conventional chemo               │
├─────────────────────┼────────────────────────────────────────────┤
│ Prior Taxane Use    │ Prior taxane + neuropathy → avoid paclitaxel│
│                     │ Taxane-naive → weekly paclitaxel preferred  │
├─────────────────────┼────────────────────────────────────────────┤
│ Prior Bevacizumab   │ Bevacizumab-naive → add bevacizumab to chemo│
│                     │ Prior bev → single-agent chemo only         │
├─────────────────────┼────────────────────────────────────────────┤
│ Existing Neuropathy │ Grade ≥2 → avoid taxanes/vinca alkaloids   │
│                     │ Prefer PLD, topotecan, gemcitabine          │
├─────────────────────┼────────────────────────────────────────────┤
│ Cardiac Function    │ Prior anthracyclines (>300mg/m² doxorubicin)│
│                     │ → avoid PLD; prefer topotecan/gemcitabine   │
├─────────────────────┼────────────────────────────────────────────┤
│ Bone Marrow Reserve │ Poor marrow → avoid topotecan (severe       │
│                     │ myelosuppression); prefer PLD, paclitaxel   │
├─────────────────────┼────────────────────────────────────────────┤
│ GI Status           │ Bowel obstruction risk → avoid bevacizumab  │
│                     │ Oral tolerance poor → prefer IV route        │
├─────────────────────┼────────────────────────────────────────────┤
│ Performance Status  │ PS 0-1 → full-dose regimens acceptable      │
│                     │ PS 2 → dose-reduced single agent            │
│                     │ PS 3-4 → best supportive care               │
├─────────────────────┼────────────────────────────────────────────┤
│ Renal Function      │ GFR <30 → avoid cisplatin; adjust topotecan │
├─────────────────────┼────────────────────────────────────────────┤
│ Alopecia preference │ PLD, gemcitabine → minimal alopecia         │
│                     │ Taxanes, topotecan → significant alopecia   │
├─────────────────────┼────────────────────────────────────────────┤
│ Infusion preference │ Oral preference → etoposide, capecitabine   │
├─────────────────────┼────────────────────────────────────────────┤
│ BRCA Status         │ BRCA-mut → PARPi option (3rd line+)         │
├─────────────────────┼────────────────────────────────────────────┤
│ Number of prior Rx  │ 1-3 lines + FRα-high → MIRV                │
│                     │ ≥4 lines → PARP or clinical trial           │
├─────────────────────┼────────────────────────────────────────────┤
│ Ocular history      │ Pre-existing ocular disease → caution MIRV  │
│                     │ Mandatory ophthalmology monitoring with MIRV │
└─────────────────────┴────────────────────────────────────────────┘

---

10. Comparative Efficacy Overview

---

11. Immunotherapy in PROC

• Pembrolizumab, nivolumab, durvalumab, atezolizumab: Phase III trials (JAVELIN Ovarian 200, NINJA trial) showed no benefit over chemotherapy in unselected populations
• Exception: dMMR/MSI-H tumors (rare, <5% of ovarian cancers) - pembrolizumab is active
• The systematic review of phase III trials (PMID 39878268, 2025) confirmed that immune checkpoint inhibitor trials showed no PFS benefit
• Combinations with bevacizumab (hypothetical synergy via normalization of tumor vasculature) are under investigation

---

12. Emerging and Investigational Approaches

VEGF/VEGFR systematic review (PMID 38218775, 2024): Anti-VEGF/VEGFR agents improved PFS in PROC but did not demonstrate OS benefit, consistent with bevacizumab findings.

---

13. NCCN 2025 Preferred Regimens (Summary)

Category 1 (Preferred):

• Mirvetuximab soravtansine - FRα-high patients, 1-3 prior lines
• Weekly paclitaxel + bevacizumab - bevacizumab-naive
• PLD + bevacizumab - bevacizumab-naive
• Topotecan + bevacizumab - bevacizumab-naive

Other Recommended (Single agent):

• Weekly paclitaxel, PLD, topotecan, gemcitabine, oral etoposide, docetaxel, capecitabine, vinorelbine

Category 3 (Other - use selectively):

• Olaparib, rucaparib, niraparib (BRCA-mutated, PARPi-naive, ≥3 prior lines)

---

14. Management by Line of Therapy

---

15. Quality of Life and Palliative Considerations

• MIRV showed significantly better patient-reported outcomes vs chemotherapy (Lancet Oncol 2025, PMID 40179908)
• Goals shift from survival to symptom management in later lines
• Hormone therapy (tamoxifen 20 mg/d, letrozole) may offer modest disease control with minimal toxicity in performance-limited patients
• Ascites management: paracentesis, PIPAC consideration
• Genetic counseling for BRCA testing in all newly diagnosed patients (impacts future therapy and family)

---

Key Takeaways

1. MIRV is now the preferred first-choice agent for FRα-high PROC - the only agent with proven OS benefit; mandatory FRα testing before decision-making
2. Single-agent chemotherapy ± bevacizumab remains the backbone for FRα-negative/low patients
3. Weekly paclitaxel + bevacizumab gives best PFS among conventional regimens (10 months in AURELIA subset)
4. PARPi role is narrowing in PROC due to safety concerns and downgraded evidence; reserve for BRCA-mutated, PARPi-naive patients
5. No OS benefit has been demonstrated for chemotherapy or bevacizumab combinations - MIRASOL/MIRV is the only exception
6. Biomarker-driven selection (FRα, BRCA, MSI status) is now the standard framework per ESMO 2026 and NCCN 2025
7. Clinical trial enrollment should be prioritized at every line

---

Key References

• MIRASOL trial (NEJM 2023): Moore KN et al., PMID 38055253 - MIRV OS benefit
• ESMO 2026 Express Update: PMC12947637 - current clinical guidelines
• AURELIA trial: Pujade-Laurain 2014 - bevacizumab + chemo in PROC
• Phase III systematic review (2025): PMID 39878268 - only MIRASOL showed OS benefit
• MIRV meta-analysis (2024): PMID 38122916 - ORR 36%, DCR 88%
• nab-Paclitaxel vs paclitaxel (2026): PMID 41611570 - nab-paclitaxel viable alternative
• VEGF/VEGFR meta-analysis (2024): PMID 38218775 - anti-angiogenics improve PFS only
• Berek & Novak's Gynecology - Chapter on ovarian cancer management, pp. 2367-2370